Assenagon Asset Management S.A. Sells 296,704 Shares of Codexis, Inc. (NASDAQ:CDXS)

Assenagon Asset Management S.A. cut its holdings in Codexis, Inc. (NASDAQ:CDXSFree Report) by 16.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,456,739 shares of the biotechnology company’s stock after selling 296,704 shares during the period. Assenagon Asset Management S.A. owned approximately 2.09% of Codexis worth $4,443,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the business. SG Americas Securities LLC raised its position in shares of Codexis by 19.1% in the 4th quarter. SG Americas Securities LLC now owns 31,442 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 5,050 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in shares of Codexis in the 3rd quarter worth about $70,000. Vanguard Group Inc. increased its position in Codexis by 9.4% in the 3rd quarter. Vanguard Group Inc. now owns 4,038,745 shares of the biotechnology company’s stock valued at $7,633,000 after buying an additional 346,913 shares in the last quarter. American Century Companies Inc. increased its position in Codexis by 39.8% in the 3rd quarter. American Century Companies Inc. now owns 28,001 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 7,973 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its position in Codexis by 27.2% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,631,864 shares of the biotechnology company’s stock valued at $3,084,000 after buying an additional 349,270 shares in the last quarter. 78.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on CDXS shares. Benchmark raised Codexis from a “hold” rating to a “buy” rating and set a $9.00 target price for the company in a research report on Thursday, February 29th. StockNews.com raised Codexis to a “sell” rating in a research report on Tuesday, March 5th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Codexis presently has an average rating of “Hold” and a consensus price target of $6.80.

Check Out Our Latest Stock Analysis on Codexis

Codexis Stock Performance

CDXS stock opened at $3.49 on Tuesday. The company has a market capitalization of $245.00 million, a P/E ratio of -3.14 and a beta of 2.01. Codexis, Inc. has a 52-week low of $1.45 and a 52-week high of $4.91. The business has a 50-day simple moving average of $3.26 and a two-hundred day simple moving average of $2.59.

Codexis (NASDAQ:CDXSGet Free Report) last released its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.18. The business had revenue of $26.56 million during the quarter, compared to the consensus estimate of $24.73 million. Codexis had a negative return on equity of 47.58% and a negative net margin of 108.69%. As a group, sell-side analysts forecast that Codexis, Inc. will post -0.6 earnings per share for the current fiscal year.

Codexis Company Profile

(Free Report)

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.

Further Reading

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.